ALVR
Price:
$0.5499
Market Cap:
$63.53M
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly ...[Read more]
Industry
Biotechnology
IPO Date
2020-07-30
Stock Exchange
NASDAQ
Ticker
ALVR
According to AlloVir, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is -53322204.00. This represents a change of -5254.60% compared to the average of 1.03M of the last 4 quarters.
The mean historical Enterprise Value of AlloVir, Inc. over the last ten years is 735.80M. The current -53322204.00 Enterprise Value has changed -824.68% with respect to the historical average. Over the past ten years (40 quarters), ALVR's Enterprise Value was at its highest in in the December 2020 quarter at 2.27B. The Enterprise Value was at its lowest in in the September 2024 quarter at -23555491.31.
Average
735.80M
Median
780.27M
Minimum
8.05M
Maximum
1.60B
Discovering the peaks and valleys of AlloVir, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 74.37%
Maximum Annual Enterprise Value = 1.60B
Minimum Annual Increase = -97.51%
Minimum Annual Enterprise Value = 8.05M
Year | Enterprise Value | Change |
---|---|---|
2023 | 8.05M | -97.51% |
2022 | 322.53M | -49.67% |
2021 | 640.81M | -30.34% |
2020 | 919.97M | -42.64% |
2019 | 1.60B | 74.37% |
The current Enterprise Value of AlloVir, Inc. (ALVR) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
323.80M
5-year avg
699.02M
10-year avg
735.80M
AlloVir, Inc.’s Enterprise Value is less than Anebulo Pharmaceuticals, Inc. (36.46M), less than Mineralys Therapeutics, Inc. (523.81M), less than AN2 Therapeutics, Inc. (6.48M), less than Aerovate Therapeutics, Inc. (46.23M), less than Adagene Inc. (22.22M), greater than Homology Medicines, Inc. (-103303255.00), less than Stoke Therapeutics, Inc. (457.69M), less than Atreca, Inc. (-8620212.00), less than Black Diamond Therapeutics, Inc. (139.97M), less than 4D Molecular Therapeutics, Inc. (197.41M), less than Acrivon Therapeutics, Inc. Common Stock (163.47M), less than Cullinan Oncology, Inc. (630.54M), less than Agios Pharmaceuticals, Inc. (2.98B), less than Crinetics Pharmaceuticals, Inc. (4.93B), less than Inhibrx Biosciences, Inc. (9.32M), less than Merus N.V. (2.68B), less than Lyell Immunopharma, Inc. (216.40M), less than Kronos Bio, Inc. (5.32M), less than AnaptysBio, Inc. (502.56M),
Company | Enterprise Value | Market cap |
---|---|---|
36.46M | $37.86M | |
523.81M | $621.09M | |
6.48M | $39.99M | |
46.23M | $76.81M | |
22.22M | $97.11M | |
-103303255.00 | $3.02M | |
457.69M | $605.41M | |
-8620212.00 | $3.57M | |
139.97M | $143.73M | |
197.41M | $360.11M | |
163.47M | $202.87M | |
630.54M | $730.17M | |
2.98B | $3.18B | |
4.93B | $5.20B | |
9.32M | $203.82M | |
2.68B | $3.11B | |
216.40M | $265.26M | |
5.32M | $54.49M | |
502.56M | $677.65M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like AlloVir, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like AlloVir, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is AlloVir, Inc.'s Enterprise Value?
What is the highest Enterprise Value for AlloVir, Inc. (ALVR)?
What is the 3-year average Enterprise Value for AlloVir, Inc. (ALVR)?
What is the 5-year average Enterprise Value for AlloVir, Inc. (ALVR)?
How does the current Enterprise Value for AlloVir, Inc. (ALVR) compare to its historical average?